GRI will release topline 12-week study data this week. All indications are that data will be positive. The price continues to test $2.2 resistance. This will be broken soon.While all price movements are relative and unique, other companies with failed IPF trials lost ~$300M in market cap upon announcement. Others with successful trails have gained billions. GRI is worth approximately $6M today. Lots of room for upward valuation.
Nota
They've missed two self-imposed deadlines to release biomarker Phase2b topline data. The delays with no explanation is unacceptable. I still, however, expect the data to be positive in nature. If no data release or statement this week I will cut it loose.Trade fechado manualmente
They released great data today, and also announced they are diluting shares by over 100% of outstanding shares, including even MORE shares in the form of warrants.GRI has no idea how to manage their stock value, or they don't care.
Aviso legal
As informações e publicações não se destinam a ser, e não constituem, conselhos ou recomendações financeiras, de investimento, comerciais ou de outro tipo fornecidos ou endossados pela TradingView. Leia mais nos Termos de Uso.
Aviso legal
As informações e publicações não se destinam a ser, e não constituem, conselhos ou recomendações financeiras, de investimento, comerciais ou de outro tipo fornecidos ou endossados pela TradingView. Leia mais nos Termos de Uso.